These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 2487171)

  • 1. Neurological features, cognitive impairment and neuroleptic response in schizophrenic patients.
    Bartkó G; Frecska E; Zádor G; Herczeg I
    Schizophr Res; 1989; 2(3):311-3. PubMed ID: 2487171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting neuroleptic response from a combination of multilevel variables in acute schizophrenic patients.
    Bartkó G; Frecska E; Horváth S; Zádor G; Arató M
    Acta Psychiatr Scand; 1990 Dec; 82(6):408-12. PubMed ID: 1981296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of repeated drug holidays on serum haloperidol concentrations, psychiatric symptoms, and movement disorders in schizophrenic patients.
    Newton JE; Cannon DJ; Couch L; Fody EP; McMillan DE; Metzer WS; Paige SR; Reid GM; Summers BN
    J Clin Psychiatry; 1989 Apr; 50(4):132-5. PubMed ID: 2925601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive disturbances in neuroleptic therapy.
    Strauss WH; Klieser E
    Acta Psychiatr Scand Suppl; 1990; 358():56-7. PubMed ID: 1978491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical response and plasma haloperidol levels in chronic and subchronic schizophrenia.
    Santos JL; Cabranes JA; Vazquez C; Fuentenebro F; Almoguera I; Ramos JA
    Biol Psychiatry; 1989 Aug; 26(4):381-8. PubMed ID: 2669981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial.
    Harvey PD; Rabinowitz J; Eerdekens M; Davidson M
    Am J Psychiatry; 2005 Oct; 162(10):1888-95. PubMed ID: 16199835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased somatostatin-like immunoreactivity in the cerebrospinal fluid of chronic schizophrenic patients with cognitive impairment.
    Reinikainen KJ; Koponen H; Jolkkonen J; Riekkinen PJ
    Psychiatry Res; 1990 Sep; 33(3):307-12. PubMed ID: 2243905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlates of rapid neuroleptic response in male patients with schizophrenia.
    Petrie EC; Faustman WO; Moses JA; Lombrozo L; Csernansky JG
    Psychiatry Res; 1990 Aug; 33(2):171-7. PubMed ID: 2243894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coadministration of fluvoxamine increases serum concentrations of haloperidol.
    Daniel DG; Randolph C; Jaskiw G; Handel S; Williams T; Abi-Dargham A; Shoaf S; Egan M; Elkashef A; Liboff S
    J Clin Psychopharmacol; 1994 Oct; 14(5):340-3. PubMed ID: 7806690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stability of neurological signs with clozapine treatment.
    Buchanan RW; Koeppl P; Breier A
    Biol Psychiatry; 1994 Aug; 36(3):198-200. PubMed ID: 7948457
    [No Abstract]   [Full Text] [Related]  

  • 11. The effect of risperidone on cognition in patients with schizophrenia.
    Stip E; Lussier I
    Can J Psychiatry; 1996 Oct; 41(8 Suppl 2):S35-40. PubMed ID: 8899249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Handedness as a risk factor for neuroleptic-induced movement disorders.
    Brown KW; White T; Anderson F; McGilp R
    Biol Psychiatry; 1992 Apr; 31(7):746-8. PubMed ID: 1350923
    [No Abstract]   [Full Text] [Related]  

  • 13. Serum prolactin as a correlate of clinical response to haloperidol.
    Van Putten T; Marder SR; Mintz J
    J Clin Psychopharmacol; 1991 Dec; 11(6):357-61. PubMed ID: 1770154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognitive changes in acute schizophrenia with brief neuroleptic treatment.
    Wahba M; Donlon PT; Meadow A
    Am J Psychiatry; 1981 Oct; 138(10):1307-10. PubMed ID: 7294185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticonvulsants as adjuncts for the neuroleptic treatment of schizophrenic psychoses: a clinical study with beclamide.
    Raptis C; Garcia-Borreguero D; Weber MM; Dose M; Bremer D; Emrich HM
    Acta Psychiatr Scand; 1990 Feb; 81(2):162-7. PubMed ID: 2183543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurological soft signs in first-episode schizophrenia: a follow-up study.
    Bachmann S; Bottmer C; Schröder J
    Am J Psychiatry; 2005 Dec; 162(12):2337-43. PubMed ID: 16330599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlations between akathisia and residual psychopathology: a by-product of neuroleptic-induced dysphoria.
    Newcomer JW; Miller LS; Faustman WO; Wetzel MW; Vogler GP; Csernansky JG
    Br J Psychiatry; 1994 Jun; 164(6):834-8. PubMed ID: 7952993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of neuroleptic treatment on symptoms of schizophrenia and plasma homovanillic acid concentrations.
    Davidson M; Kahn RS; Knott P; Kaminsky R; Cooper M; DuMont K; Apter S; Davis KL
    Arch Gen Psychiatry; 1991 Oct; 48(10):910-3. PubMed ID: 1929760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia.
    Fenton WS; Dickerson F; Boronow J; Hibbeln JR; Knable M
    Am J Psychiatry; 2001 Dec; 158(12):2071-4. PubMed ID: 11729030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Course of recovery of cognitive impairment in patients with schizophrenia: a randomised double-blind study comparing sertindole and haloperidol.
    Gallhofer B; Jaanson P; Mittoux A; Tanghøj P; Lis S; Krieger S
    Pharmacopsychiatry; 2007 Nov; 40(6):275-86. PubMed ID: 18030652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.